Plasma interleukin-6 is associated with coagulation in poorly controlled patients with Type 2 diabetes

Diabetic Medicine

Volumn 20, Issue 11, 2003, Pages 930-934

  Aso, Yoshimasa ^a   Okumura, K ^a   Yoshida, N ^a   Tayama, K ^a   Kanda, T ^b   Kobayashi, I ^c   Takemura, Y ^a   Inukai, T ^a  

^a DOKKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

^c GUNMA UNIVERSITY   (Japan)

Author keywords

Coagulation; D dimer; Inflammation; Interleukin 6; Type 2 diabetes

Indexed keywords

D DIMER; FIBRINOGEN; INSULIN; INTERLEUKIN 6; SULFONYLUREA; FIBRIN DEGRADATION PRODUCT; SULFONYLUREA DERIVATIVE;

ARTICLE; BLOOD CLOTTING; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES CONTROL; GLUCOSE BLOOD LEVEL; HOSPITALIZATION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; WEIGHT REDUCTION; BLOOD; FEMALE; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY;

BLOOD COAGULATION; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; HOSPITALIZATION; HUMANS; INSULIN; INTERLEUKIN-6; MALE; MIDDLE AGED; SULFONYLUREA COMPOUNDS;

EID: 1542498650     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.2003.01058.x     Document Type: Article

References (32)

1. Kannel WB, MacGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care 1979; 2: 120-126.
2. Uusitupa MI, Niskanen LK, Siitonen O, Voutilainen E, Pyorala K. 5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and non-diabetic subjects. Circulation 1990; 82: 27-36.
3. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and nondiabetic subjects and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
4. Folsom AR. Haemostatic risk factors for atherothrombotic disease: an epidemiologic view. Thromb Haemost 2001; 86: 366-373.
5. Ross R. Atherosclerosis-An inflammatory disease. N Engl J Med 1999; 340: 115-125.
6. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997; 349: 462-466.
7. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-505.
8. Toss H, Lindahl B, Siegbahn A, Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during instability in coronary artery disease. Circulation 1997; 96: 4204-4210.
9. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993; 118: 956-963.
10. Ridker PM, Hennekens CH, Cerskus A, Stampfer MJ. Plasma concentration of cross-linked fibrin degradation product (D-Dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation 1994; 90: 2236-40.
11. Lowe GD, Yarnell JW, Rumley A, Bainton D, Sweetnam PM. C-reactive protein, fibrin D-Dimer, and incident ischemic heart disease in the Speedwell study, are inflammation and fibrin turnover linked inpathogenesis? Arterioscler Thromb Vasc Biol 2001; 21: 603-610.
12. Lowe GDO, Rumley A. Use of fibrinogen and fibrin D dimer in prediction of arterial thrombotic events. Thromb Haemost 1999; 82: 667-672.
13. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990; 265: 621-636.
14. Neumann FJ, Ott I, Marx N, Luther T, Kenngott S, Gawaz M et al. Effect of human recombinant interIeukin-6 and interleukin-8 on monocyte procoagulant activity. Arterioscler Thromb Vasc Biol 1997; 17: 3399-3405.
15. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767-1772.
16. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system, association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997; 40: 1286-1292.
17. American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care, 1997; 20: 1183-1197.
18. Crofford LJ, Kalogeras KT, Mastorakos G, Magiakou MA, Wells J, Kanik KS et al. Circadian relationships between interleukin (IL)-6 and hypothalamic-pituitary-adrenal axis hormones: failure of IL-6 to cause sustained hypercortisolism in patients with early untreated rheumatoid arthritis. J Clin Endocrinol Metab 1997; 82: 1279-1283.
19. Jafri SM, VanRollins M, Ozawa T, Mammen EF, Goldberg AD, Goldstein S. Circadian variation in platelet function in healthy volunteers. Am J Cardiol 1992; 69: 951-954.
20. Morohoshi M, Fujisawa K, Uchimura I, Numano F. Glucose-dependent interleukin 6 and tumor necrosis factor production by human peripheral blood monocytes in vitro. Diabetes 1996; 45: 954-959.
21. Yudkin JS, Panahloo A, Stehouwer C, Emeis JJ, Bulmer K, Mohamed-Ali V et al. The influence of improved glycaemic control with insulin and sulphonylureas on acute phase and endothelial markers in Type II diabetic subjects. Diabetologia 2000; 43: 1099-1106.
22. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997; 82: 4196-4200.
23. Bastard JP, Jardel C, Bruckert E, Blondy P, Capeau J, Laville M et al. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 2000; 85: 3338-3342.
24. Soop M, Duxbury H, Agwunobi AO, Gibson JM, Hopkins SJ, Childs C et al. Euglycemic hyperinsulinemia augments the cytokine and endocrine responses to endotoxin in humans. Am J Physiol Endocrinol Metab 2002; 282: E1276-E1285.
25. Baumann H, Gauldie J. The acute phase response. Immunol Today 1994; 15: 74-80.
26. Matsuo T, Kobayashi H, Kario K, Suzuki S. Fibrin D dimer in thrombogenic disorders. Semin Thromb Hemost 2000; 26: 101-117.
27. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P et al. Fibrin D-Dimer and coronary heart disease, prospective study and meta-analysis. Circulation 2001; 103: 2323-2327.
28. Aso Y, Fujiwara Y, Tayama K, Takebayashi K, Inukai T, Takemura Y. Relationship between soluble thrombomodulin in plasma and coagulation or fibrinolysis in type 2 diabetes. Clin Chim Acta 2000; 301: 135-145.
29. Mestries JC, Kruithof EK, Gascon MP, Herodin F, Agay D, Ythier A. In vivo modulation of coagulation and fibrinolysis by recombinant glycosylated human interleukin-6 in baboons. Eur Cytokine Netw 1994; 5: 275-281.
30. Robson SC, Shepard EG, Kirsch RE. Fibrin degradation product D-Dimer induces the synthesis of biologically active IL-1β, and IL-6 and plasminogen activator inhibitors from monocytes in vitro. Br J Haematol 1994; 86: 322-326.
31. Smith EB. Fibrinogen, fibrin and fibrin degradation products in relation to atherosclerosis. Clin Haematol 1986; 15: 355-370.
32. Ganda OP, Arkin CF. Hyperfibrinogenemia. An important risk factor for vascular complications in diabetes. Diabetes Care 1992; 15: 1245-1250.